Research on Innovative Traditional Chinese Medicine Diagnosis and Treatment Technologies for Diabetic Nephropathy Driven by Multi-Omics and Artificial Intelligence

Inclusion Criteria: 1. Meets the clinical diagnostic criteria for diabetic nephropathy; 2. Aged 18-75 years, any gender; 3. eGFR \>45 ml/min/1.73m²; 4. 24-hour urine protein \<2.0 g/day; 5. Exhibits Traditional Chinese Medicine patterns of deficiency, stasis, or rheumatic symptoms; 6. Willing to participate in the study, able to attend regular follow-ups, and provide informed consent; 7. Has maintained a stable basic treatment plan (including hypoglycemic, antihypertensive, and lipid-lowering therapies) for ≥1 month prior to enrollment; during the first 3 months after enrollment, ARB, finerenone, and SGLT2 inhibitor therapies should generally not be adjusted. Exclusion Criteria: 1. Acute kidney injury or renal function impairment caused by other reasons (recent rapid decline in renal function, or kidney damage caused by drugs, infections, etc.); 2. Other primary or secondary kidney diseases (such as systemic lupus erythematosus, polycystic kidney disease, etc.); 3. Uncontrolled severe complications (such as severe cardiovascular disease, uncontrolled hypertension, severe infections, etc.); 4. Critical organ failure (severe diseases of the heart, liver, or lungs); 5. Pregnancy or planned pregnancy (women currently pregnant or planning to become pregnant during the study); 6. Drug allergy or clear contraindications (allergic to the study drug or its components); 7. Non-cooperative or unable to follow the study protocol (unable or unwilling to comply with study requirements); 8. Abnormal coagulation function, or undergoing anticoagulant therapy (such as warfarin, rivaroxaban, etc.) with bleeding risk; 9. Currently taking Chinese herbal medicine or patent Chinese medicine with effects of tonifying deficiency, promoting blood circulation, or dispelling wind-dampness.